Description
Composition- Sitagliptin 50 mg
Mode of Action- DPP-4 inhibition prolongs endogenous incretin effect, improving glucose-dependent insulin release and lowering glucagon secretion.
USPs- Lower strength DPP-4 support; useful in titration and individualized diabetes care; low hypoglycemia tendency.
Prescribing Specialties- Diabetologist, General Physician
